SG Americas Securities LLC Has $141.68 Million Stock Position in Becton, Dickinson and Company $BDX

SG Americas Securities LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 205.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 730,054 shares of the medical instruments supplier’s stock after buying an additional 491,255 shares during the period. SG Americas Securities LLC’s holdings in Becton, Dickinson and Company were worth $141,682,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. TABR Capital Management LLC acquired a new position in Becton, Dickinson and Company in the 4th quarter worth about $3,814,000. Dynamic Advisor Solutions LLC acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at about $213,000. Norway Savings Bank boosted its stake in shares of Becton, Dickinson and Company by 2.4% during the fourth quarter. Norway Savings Bank now owns 6,712 shares of the medical instruments supplier’s stock valued at $1,303,000 after purchasing an additional 155 shares in the last quarter. True Wealth Design LLC grew its holdings in shares of Becton, Dickinson and Company by 27.1% during the fourth quarter. True Wealth Design LLC now owns 521 shares of the medical instruments supplier’s stock worth $101,000 after purchasing an additional 111 shares during the last quarter. Finally, M. Kulyk & Associates LLC increased its stake in shares of Becton, Dickinson and Company by 2.6% in the fourth quarter. M. Kulyk & Associates LLC now owns 42,788 shares of the medical instruments supplier’s stock valued at $8,304,000 after buying an additional 1,075 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on BDX shares. Argus dropped their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday. Jefferies Financial Group decreased their price target on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Barclays started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price target for the company. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Finally, Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $191.62.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,787 shares of company stock worth $551,391 in the last ninety days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $156.01 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a 50 day simple moving average of $184.60 and a two-hundred day simple moving average of $188.57. The company has a market capitalization of $44.42 billion, a PE ratio of 25.45, a P/E/G ratio of 11.17 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the company earned $3.43 EPS. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is 68.52%.

Becton, Dickinson and Company declared that its board has initiated a share repurchase program on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.